Alector entered an exclusive global license with Genentech for AL050, a brain-penetrant GCase enzyme replacement therapy enabled by Alector's ABC platform. The deal provides $100 million upfront and up to $1.17 billion in milestones, plus royalties, extending ALEC’s cash runway to 2029 and funding additional programs. Genentech will lead development and commercialization, while ALEC retains ABC rights for its broader pipeline.
GSK terminated its neuroscience collaboration with Alector on two experimental antibody drugs after both candidates faced clinical setbacks. The breakup could trim near-term upside for Alector but may free resources for other programs or partnerships. Investors will focus on potential milestone, royalty implications, data readouts, and any new collaboration opportunities.
Alector's trial failed to meet co-primary endpoints for frontotemporal dementia. Stock dropped 51% to $1.57, nearing its 52-week low. Company reducing workforce by 49% amid ongoing trials. William Blair downgraded ALEC from Outperform to Market Perform. Cash reserves expected to last through 2027 despite recent setbacks.
Alector's experimental drug failed in a late-stage trial, ending the study. The company plans to lay off nearly half its workforce due to this failure.
Bank of America downgraded Alector due to AL002 program failure. AL002 missed primary endpoint in Alzheimer’s Phase 2 trial. Expected Phase 3 trial results may take until late 2025. Limited near-term milestones pressure Alector's stock performance. Analyst reduced price target from $9 to $1.
Alector's AL002 failed to slow Alzheimer's progression in Phase 2 trial. No positive effects on clinical endpoints; treatment caused MRI abnormalities. Company is stopping the long-term study and cutting workforce by 17%. Alector has $457.2 million cash, expected to fund operations through 2026. Analysts predict AbbVie may opt out of AL002 collaboration due to trial failure.
